DK3126390T3 - Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi - Google Patents

Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi Download PDF

Info

Publication number: DK3126390T3
Authority: DK; Denmark
Prior art keywords: immuniation; cancer; specific chemical; antigen receptors; chemical antigen
Prior art date: 2014-04-03

Application number

DK15713513.8T

Other languages

English (en)

Inventor

Roman Galetto

Original Assignee

Cellectis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-03

Filing date

2015-04-02

Publication date

2020-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50486692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3126390(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-02 Application filed by Cellectis filed Critical Cellectis

2020-01-20 Application granted granted Critical

2020-01-20 Publication of DK3126390T3 publication Critical patent/DK3126390T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK15713513.8T 2014-04-03 2015-04-02 Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi DK3126390T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201470171		2014-04-03
PCT/EP2015/057331 WO2015150526A2 (en)	2014-04-03	2015-04-02	Cd33 specific chimeric antigen receptors for cancer immunotherapy

Publications (1)

Publication Number	Publication Date
DK3126390T3 true DK3126390T3 (da)	2020-01-20

Family

ID=50486692

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15713513.8T DK3126390T3 (da)	2014-04-03	2015-04-02	Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi

Country Status (13)

Country	Link
US (3)	US9944702B2 (da)
EP (1)	EP3126390B1 (da)
JP (1)	JP6673848B2 (da)
KR (1)	KR102170533B1 (da)
CN (1)	CN106795221B (da)
AU (1)	AU2015239069B2 (da)
CA (1)	CA2944528C (da)
DK (1)	DK3126390T3 (da)
ES (1)	ES2765710T3 (da)
IL (1)	IL247917B (da)
MX (1)	MX370788B (da)
RU (1)	RU2701341C2 (da)
WO (1)	WO2015150526A2 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
US10689609B2 (en)	2012-03-15	2020-06-23	Flodesign Sonics, Inc.	Acoustic bioreactor processes
US10967298B2 (en)	2012-03-15	2021-04-06	Flodesign Sonics, Inc.	Driver and control for variable impedence load
US9752113B2 (en)	2012-03-15	2017-09-05	Flodesign Sonics, Inc.	Acoustic perfusion devices
US9745548B2 (en)	2012-03-15	2017-08-29	Flodesign Sonics, Inc.	Acoustic perfusion devices
US10322949B2 (en)	2012-03-15	2019-06-18	Flodesign Sonics, Inc.	Transducer and reflector configurations for an acoustophoretic device
US9458450B2 (en)	2012-03-15	2016-10-04	Flodesign Sonics, Inc.	Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en)	2012-03-15	2018-04-24	Flodesign Sonics, Inc.	Electronic configuration and control for acoustic standing wave generation
US10737953B2 (en)	2012-04-20	2020-08-11	Flodesign Sonics, Inc.	Acoustophoretic method for use in bioreactors
US9745569B2 (en)	2013-09-13	2017-08-29	Flodesign Sonics, Inc.	System for generating high concentration factors for low cell density suspensions
CA2935960C (en)	2014-01-08	2023-01-10	Bart Lipkens	Acoustophoresis device with dual acoustophoretic chamber
DK3126390T3 (da) *	2014-04-03	2020-01-20	Cellectis	Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi
US10316101B2 (en) *	2014-04-14	2019-06-11	Cellectis	BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
US9744483B2 (en)	2014-07-02	2017-08-29	Flodesign Sonics, Inc.	Large scale acoustic separation device
EP3172234B1 (en) *	2014-07-21	2020-04-08	Novartis AG	Treatment of cancer using a cd33 chimeric antigen receptor
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
US11021699B2 (en)	2015-04-29	2021-06-01	FioDesign Sonics, Inc.	Separation using angled acoustic waves
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
US11459540B2 (en)	2015-07-28	2022-10-04	Flodesign Sonics, Inc.	Expanded bed affinity selection
US11474085B2 (en)	2015-07-28	2022-10-18	Flodesign Sonics, Inc.	Expanded bed affinity selection
IL300420B2 (en)	2015-10-16	2024-09-01	Univ Columbia	Compositions and methods for inhibition of lineage specific antigens
WO2017172981A2 (en) *	2016-03-29	2017-10-05	University Of Southern California	Chimeric antigen receptors targeting cancer
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
US11085035B2 (en)	2016-05-03	2021-08-10	Flodesign Sonics, Inc.	Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11787848B2 (en) *	2016-06-08	2023-10-17	Precigen, Inc.	CD33 specific chimeric antigen receptors
JP2020513248A (ja)	2016-10-19	2020-05-14	フロデザインソニックス，インク．ＦｌｏｄｅｓｉｇｎＳｏｎｉｃｓ，Ｉｎｃ．	音響による親和性細胞抽出
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
KR102709603B1 (ko)	2017-02-28	2024-09-27	보르 바이오파마 인크.	계통 특이적 단백질의 억제를 위한 조성물 및 방법
US10426797B2 (en) *	2017-03-24	2019-10-01	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-CD33 immunotherapy
KR20190142775A (ko)	2017-04-19	2019-12-27	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	조작된 항원 수용체를 발현하는 면역 세포
AU2018258027A1 (en) *	2017-04-24	2019-10-24	Memorial Sloan Kettering Cancer Center	Anti-CD33 antibody agents
US11807662B2 (en)	2017-05-16	2023-11-07	The Johns Hopkins University	MANAbodies and methods of using
JP7252651B2 (ja)	2017-07-20	2023-04-05	エイチリーモフィットキャンサーセンターアンドリサーチインスティテュートインコーポレイテッド	Ｃｄ３３発現がんを標的とするための組成物および方法
WO2019067677A1 (en)	2017-09-29	2019-04-04	Cell Design Labs, Inc.	METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR
WO2019084234A1 (en) *	2017-10-26	2019-05-02	St. Jude Childen's Research Hospital, Inc.	METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
GB201719646D0 (en) *	2017-11-27	2018-01-10	Bivictrix Therapeutics Ltd	Therapy
WO2019113031A1 (en) *	2017-12-04	2019-06-13	Actinium Pharmaceuticals Inc.	Methods for treatment of patients with myelodyplastic syndromes
WO2019118921A1 (en)	2017-12-14	2019-06-20	Flodesign Sonics, Inc.	Acoustic transducer drive and controller
CN108047333B (zh) *	2018-01-15	2021-05-25	浙江阿思科力生物科技有限公司	以cd33为靶点的特异性抗体、car-nk细胞及其制备和应用
SG11202008796VA (en) *	2018-03-14	2020-10-29	The United States Of America As Represented By The Secretary	Anti-cd33 chimeric antigen receptors and their uses
US20210015864A1 (en)	2018-03-23	2021-01-21	Kite Pharma, Inc.	Chimeric transmembrane proteins and uses thereof
US10869888B2 (en)	2018-04-17	2020-12-22	Innovative Cellular Therapeutics CO., LTD.	Modified cell expansion and uses thereof
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) *	2018-04-18	2020-11-25	Hoffmann La Roche	Anticuerpos multiespecíficos y utilización de los mismos
CN110551741A (zh) *	2018-06-01	2019-12-10	上海恒润达生生物科技有限公司	靶向cd33的嵌合抗原受体及其用途
US11319380B2 (en) *	2018-06-04	2022-05-03	Precigen, Inc.	MUC16 specific chimeric antigen receptors and uses thereof
US20220403001A1 (en)	2018-06-12	2022-12-22	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
AU2019288733C1 (en)	2018-06-22	2023-08-03	Kite Pharma, Inc.	Chimeric transmembrane proteins and uses thereof
CN110856724B (zh) *	2018-08-24	2022-05-27	杭州康万达医药科技有限公司	包含核酸及car修饰的免疫细胞的治疗剂及其应用
JP2022520138A (ja)	2018-08-28	2022-03-29	ブイオーアールバイオファーマインコーポレーテッド	遺伝子操作された造血幹細胞およびそれらの使用
US12240915B2 (en)	2018-08-30	2025-03-04	Innovative Cellular Therapeutics Holdings, Ltd.	Chimeric antigen receptor cells for treating solid tumor
WO2020056170A1 (en) *	2018-09-12	2020-03-19	Fred Hutchinson Cancer Research Center	Reducing cd33 expression to selectively protect therapeutic cells
WO2020086742A1 (en)	2018-10-24	2020-04-30	Obsidian Therapeutics, Inc.	Er tunable protein regulation
CA3118816A1 (en) *	2018-11-07	2020-05-14	Crispr Therapeutics Ag	Anti-cd33 immune cell cancer therapy
WO2020150478A1 (en) *	2019-01-16	2020-07-23	The Trustees Of Columbia University In The City Of New York	Compositions and methods for inhibition of lineage specific antigens
US20220195441A1 (en) *	2019-04-25	2022-06-23	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
CN114007642A (zh)	2019-04-30	2022-02-01	森迪生物科学公司	嵌合受体及其使用方法
BR112021022356A2 (pt) *	2019-05-08	2022-01-18	2Seventy Bio Inc	Imunoterapias direcionadas a cd33
US20220213489A1 (en) *	2019-05-31	2022-07-07	City Of Hope	Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies
EP3986922A2 (en)	2019-06-21	2022-04-27	Kite Pharma, Inc.	Tgf-beta receptors and methods of use
WO2021046451A1 (en)	2019-09-06	2021-03-11	Obsidian Therapeutics, Inc.	Compositions and methods for dhfr tunable protein regulation
US12076343B2 (en)	2020-02-19	2024-09-03	Innovative Cellular Therapeutics Holdings, Ltd.	Engineered safety in cell therapy
CA3172691A1 (en) *	2020-03-31	2021-10-07	Cameron J. Turtle	Chimeric antigen receptors targeting cd33
US12043654B2 (en)	2020-06-02	2024-07-23	Innovative Cellular Therapeutics Holdings, Ltd.	Anti-GCC antibody and CAR thereof for treating digestive system cancer
TW202241935A (zh)	2020-12-18	2022-11-01	美商世紀治療股份有限公司	具有可調適受體專一性之嵌合抗原受體系統
WO2022266075A1 (en)	2021-06-14	2022-12-22	Caribou Biosciences, Inc.	Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
CN113527435B (zh) *	2021-07-14	2022-06-07	呈诺再生医学科技(珠海横琴新区)有限公司	对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用
GB202204386D0 (en) *	2022-03-28	2022-05-11	Cambridge Entpr Ltd	Engineered immune cell platform
WO2025008108A1 (en)	2023-07-06	2025-01-09	Miltenyi Biotec B.V. & Co. KG	Immune cell expressing chimeric antigen receptor and transgenic t cell receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030229208A1 (en)	1988-12-28	2003-12-11	Protein Design Labs, Inc.	Humanized immunoglobulins
PT659439E (pt) *	1993-12-24	2002-04-29	Merck Patent Gmbh	Imunoconjugados
CN1795009B (zh) *	2002-11-07	2014-07-09	伊谬诺金公司	抗-cd33抗体及其用途
DE102009045006A1 (de) *	2009-09-25	2011-04-14	Technische Universität Dresden	Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
WO2011056894A2 (en) *	2009-11-03	2011-05-12	Jensen Michael C	TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
ES2774160T3 (es) *	2012-02-13	2020-07-17	Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute	Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
US20130309223A1 (en)	2012-05-18	2013-11-21	Seattle Genetics, Inc.	CD33 Antibodies And Use Of Same To Treat Cancer
CA2874611C (en)	2012-05-25	2023-01-24	Cellectis	Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
DK3126390T3 (da) *	2014-04-03	2020-01-20	Cellectis	Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi
US10316101B2 (en) *	2014-04-14	2019-06-11	Cellectis	BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

2015
- 2015-04-02 DK DK15713513.8T patent/DK3126390T3/da active
- 2015-04-02 CA CA2944528A patent/CA2944528C/en active Active
- 2015-04-02 JP JP2016560555A patent/JP6673848B2/ja active Active
- 2015-04-02 KR KR1020167030892A patent/KR102170533B1/ko active Active
- 2015-04-02 AU AU2015239069A patent/AU2015239069B2/en active Active
- 2015-04-02 MX MX2016012855A patent/MX370788B/es active IP Right Grant
- 2015-04-02 CN CN201580027233.3A patent/CN106795221B/zh active Active
- 2015-04-02 US US15/301,686 patent/US9944702B2/en active Active
- 2015-04-02 RU RU2016143155A patent/RU2701341C2/ru active
- 2015-04-02 EP EP15713513.8A patent/EP3126390B1/en active Active
- 2015-04-02 ES ES15713513T patent/ES2765710T3/es active Active
- 2015-04-02 WO PCT/EP2015/057331 patent/WO2015150526A2/en active Application Filing
2016
- 2016-09-19 IL IL247917A patent/IL247917B/en active IP Right Grant
2018
- 2018-03-20 US US15/926,755 patent/US20190002561A1/en not_active Abandoned
2023
- 2023-10-26 US US18/495,109 patent/US20240182565A1/en active Pending

Also Published As

Publication number	Publication date
US20190002561A1 (en)	2019-01-03
ES2765710T3 (es)	2020-06-10
BR112016022369A2 (pt)	2017-10-10
JP2017515460A (ja)	2017-06-15
AU2015239069B2 (en)	2020-02-20
MX2016012855A (es)	2016-12-12
AU2015239069A1 (en)	2016-10-06
CN106795221B (zh)	2022-06-07
RU2701341C2 (ru)	2019-09-25
KR20170002412A (ko)	2017-01-06
IL247917A0 (en)	2016-11-30
US9944702B2 (en)	2018-04-17
KR102170533B1 (ko)	2020-10-27
EP3126390A2 (en)	2017-02-08
WO2015150526A2 (en)	2015-10-08
IL247917B (en)	2020-11-30
RU2016143155A (ru)	2018-05-04
CA2944528C (en)	2021-08-10
RU2016143155A3 (da)	2018-10-23
CA2944528A1 (en)	2015-10-08
US20170145094A1 (en)	2017-05-25
JP6673848B2 (ja)	2020-03-25
EP3126390B1 (en)	2019-10-16
CN106795221A (zh)	2017-05-31
MX370788B (es)	2020-01-06
WO2015150526A3 (en)	2015-11-26
US20240182565A1 (en)	2024-06-06

Publication	Publication Date	Title
DK3126390T3 (da)	2020-01-20	Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi
HK1245801B (zh)	2020-05-15	Bcma嵌合抗原受體
DK3194434T3 (da)	2019-08-26	Kimære antigenreceptorer
DK3274366T3 (da)	2020-02-10	Kimær antigenreceptor
DK3119807T3 (da)	2019-07-15	Cd123-specifikke kimære antigenreceptorer til cancerimmunterapi
IL250043A0 (en)	2017-03-30	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
IL248257A0 (en)	2016-11-30	Humanized antibodies against cd269(bcma)
DK3105335T3 (da)	2020-01-13	Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
DK3453406T3 (da)	2021-07-12	ROR1(NTRKR1)-specifikke kimære antigenreceptorer til cancerimmunterapi
BR112017001385A2 (pt)	2018-06-05	anticorpos anti-pd-1
DK3126395T3 (da)	2019-09-30	Multispecifikke antistoffer
HUE046027T2 (hu)	2020-01-28	Multispecifikus ellenanyag-konstrukciók
DK3134432T3 (da)	2020-03-30	Kimære antigenreceptorer med mnd-promoter
DK3594238T3 (da)	2021-04-19	Antistofsammensætninger til tumorbehandling
SI3230310T1 (sl)	2019-11-29	Anti-CD70 himerni antigenski receptorji
PT3101032T (pt)	2019-04-03	Onjugado de anticorpo anti-her2-fármaco
DK3140653T3 (da)	2022-06-20	Direkte immunhistokemianalyse
IL248402A0 (en)	2016-11-30	Humanized antibodies against ceacam1
DK3125898T3 (da)	2020-03-30	Farmakofor til trail-induktion
RS59805B1 (sr)	2020-02-28	Unapređena il-6 antitela
LT3092003T (lt)	2020-01-27	Naujas anti-netrino-1 antikūnas
LT3178931T (lt)	2021-04-12	Anti-orai1 antikūnas
LT3628731T (lt)	2021-08-10	Naujas antipresepsino antikūnas
LT3126391T (lt)	2020-02-10	Hpa-1a antikūnai
TH1701000338A (th)	2023-03-20	บีซีเอ็มเอ ไคเมอริคแอนติเจนรีเซฟเตอร์ (bcma chimeric antigen receptors)